表紙:世界のアダリムマブ市場:2027年までの業界動向と予測
市場調査レポート
商品コード
977591

世界のアダリムマブ市場:2027年までの業界動向と予測

Global Adalimumab Market - Industry Trends and Forecast to 2027

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 357 Pages | 納期: 3-5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.28円
世界のアダリムマブ市場:2027年までの業界動向と予測
出版日: 2020年11月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 357 Pages
納期: 3-5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアダリムマブの市場規模は、2020年から2027年の予測期間に4.8%のCAGRで拡大すると予測されています。この新しい市場レポートには、2018年の実績と、2019年を基準年とした2020年から2027年までの予測データが含まれています。

当レポートでは、世界のアダリムマブ市場について調査し、市場の概要とともに、適応別、タイプ別、有効性成分含量別、薬剤タイプ別、投与ルート別、人口タイプ別、エンドユーザー別、流通チャネル別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

  • パイプライン分析

第4章 世界のアダリムマブ市場の規制の枠組み

第5章 疫学

第6章 アダリムマブの処方

第7章 世界のアダリムマブ市場:償還シナリオ

  • 米国での償還シナリオ
  • 中国の償還シナリオ
  • 日本の償還シナリオ
  • 中央および東欧での償還シナリオ
  • デンマークの償還シナリオ
  • アイルランドの償還シナリオ

第8章 バイオシミラーの影響

第9章 市場概要

  • 促進要因
    • リウマチ性関節リウマチの有病率の上昇
    • 高齢者人口の増加
    • CROの増加
    • バイオシミラーの導入
    • 新興市場の調査
  • 抑制要因
    • 薬剤コストの高さ
    • 薬剤の副作用
    • 癌の原因となる薬剤
  • 市場機会
    • 製品パイプラインの存在
    • 市場参加者による戦略的イニシアチブ
    • 医療費高騰
    • 償還政策の存在
  • 課題
    • 特許の喪失
    • 代替案の入手可能性
    • 長期的な承認手続き

第10章 ヘルスケア業界におけるCOVID-19のアダリムマブへの影響

  • 概要
  • アダリムマブとCOVID-19
  • COVID-19の価格への影響
  • 需要への影響
  • サプライチェーンへの影響
  • 製造業者のための戦略的決定
  • 結論

第11章 世界のアダリムマブ市場、適応別

  • 概要
  • 関節リウマチ
  • 強直性脊椎炎
  • 慢性尋常性乾癬
  • クローン病
  • 潰瘍性大腸炎
  • 乾癬性関節炎
  • 若年性特発性関節炎
  • 化膿性汗腺炎
  • 非感染性中級者
  • その他

第12章 世界のアダリムマブ市場、タイプ別

  • 概要
  • 生物学
  • バイオシミラー
    • アダリムマブ-ATTO
    • アダリムマブ-BWWD
    • アダリムマブ-ADBM
    • アダリムマブ-ADAZ
    • アダリムマブ-FKJP
    • アダリムマブ-AFZB
    • その他

第13章 世界のアダリムマブ市場、有効性成分含量別

  • 概要
  • 40MG / 0.4ML
  • 80MG / 0.8ML
  • 20MG / 0.4ML
  • 10MG / 0.1ML
  • その他

第14章 世界のアダリムマブ市場、薬剤タイプ別

  • 概要
  • ブランド薬
  • ジェネリック薬
    • AMJEVITA
    • HYRIMOZ
    • HULIO
    • その他

第15章 世界のアダリムマブ市場、投与ルート別

  • 概要
  • 非経口
  • 経口

第16章 世界のアダリムマブ市場、人口タイプ別

  • 概要
  • 成人
  • 小児

第17章 世界のアダリムマブ市場、エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック
  • ヘルスケア
  • その他

第18章 世界のアダリムマブ市場、流通チャネル別

  • 概要
  • 院内薬局
  • 小売薬局
  • オンライン薬局
  • 直接入札
  • その他

第19章 世界のアダリムマブ市場、地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • オランダ
    • ロシア
    • スイス
    • ベルギー
    • トルコ
    • オーストリア
    • ノルウェー
    • ハンガリー
    • リトアニア
    • アイルランド
    • ポーランド
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • 韓国
    • オーストラリア
    • インド
    • シンガポール
    • マレーシア
    • タイ
    • インドネシア
    • フィリピン
    • ベトナム
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • ペルー
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • イスラエル
    • クウェート
    • エジプト
    • その他

第20章 世界のアダリムマブ市場、競合情勢

  • 企業シェア分析:世界
  • 企業シェア分析:北米
  • 企業シェア分析:欧州
  • 企業シェア分析:アジア太平洋

21章: SWOT

第22章 企業プロファイル

  • ABBVIE INC.
  • AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)
  • BIOGEN
  • SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG))
  • MYLAN N.V.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CELLTRION INC.
  • COHERUS BIOSCIENCES
  • FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)
  • HETERO BIOPHARMA LTD.
  • INNOVENT BIOLOGICS, INC.
  • PFIZER INC.
  • RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)
  • SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)
  • ZYDUS CADILA

第23章 アンケート

第24章 関連レポート

図表

LIST OF FIGURES

  • FIGURE 1 GLOBAL ADALIMUMAB MARKET: SEGMENTATION 43
  • FIGURE 2 GLOBAL ADALIMUMAB MARKET: DATA TRIANGULATION 46
  • FIGURE 3 GLOBAL ADALIMUMAB MARKET: DROC ANALYSIS 47
  • FIGURE 4 GLOBAL ADALIMUMAB MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 48
  • FIGURE 5 GLOBAL ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS 48
  • FIGURE 6 GLOBAL ADALIMUMAB MARKET: MULTIVARIATE MODELLING 49
  • FIGURE 7 GLOBAL ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS 50
  • FIGURE 8 GLOBAL ADALIMUMAB MARKET: DBMR MARKET POSITION GRID 51
  • FIGURE 9 GLOBAL ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS 52
  • FIGURE 10 GLOBAL ADALIMUMAB MARKET: SEGMENTATION 56
  • FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE HIGHEST GROWING REGION IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 57
  • FIGURE 12 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 58
  • FIGURE 13 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ADALIMUMAB MARKET IN 2020 & 2027 58
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN GLOBAL ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 59
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL ADALIMUMAB MARKET 70
  • FIGURE 16 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS) 73
  • FIGURE 17 FUNCTION OF CRO 73
  • FIGURE 18 HEALTHCARE EXPENDITURE IN 2016 AND 2019 79
  • FIGURE 19 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019 87
  • FIGURE 20 GLOBAL ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION) 88
  • FIGURE 21 GLOBAL ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027) 88
  • FIGURE 22 GLOBAL ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE 89
  • FIGURE 23 GLOBAL ADALIMUMAB MARKET: BY TYPE, 2019 100
  • FIGURE 24 GLOBAL ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION) 101
  • FIGURE 25 GLOBAL ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027) 101
  • FIGURE 26 GLOBAL ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE 102
  • FIGURE 27 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019 107
  • FIGURE 28 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION) 108
  • FIGURE 29 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027) 108
  • FIGURE 30 GLOBAL ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE 109
  • FIGURE 31 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, 2019 115
  • FIGURE 32 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION) 116
  • FIGURE 33 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027) 116
  • FIGURE 34 GLOBAL ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE 117
  • FIGURE 35 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019 121
  • FIGURE 36 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION) 122
  • FIGURE 37 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 122
  • FIGURE 38 GLOBAL ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 123
  • FIGURE 39 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019 127
  • FIGURE 40 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION) 128
  • FIGURE 41 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027) 128
  • FIGURE 42 GLOBAL ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE 129
  • FIGURE 43 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019 133
  • FIGURE 44 GLOBAL ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION) 134
  • FIGURE 45 GLOBAL ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027) 134
  • FIGURE 46 GLOBAL ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE 135
  • FIGURE 47 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019 140
  • FIGURE 48 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 141
  • FIGURE 49 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 141
  • FIGURE 50 GLOBAL ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 142
  • FIGURE 51 GLOBAL ADALIMUMAB MARKET: SNAPSHOT (2019) 149
  • FIGURE 52 GLOBAL ADALIMUMAB MARKET: BY REGION (2019) 151
  • FIGURE 53 GLOBAL ADALIMUMAB MARKET: BY REGION (2020 & 2027) 151
  • FIGURE 54 GLOBAL ADALIMUMAB MARKET: BY REGION (2019 & 2027) 152
  • FIGURE 55 GLOBAL ADALIMUMAB MARKET: BY INDICATION (2020-2027) 152
  • FIGURE 56 NORTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019) 154
  • FIGURE 57 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019) 156
  • FIGURE 58 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 156
  • FIGURE 59 NORTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 157
  • FIGURE 60 NORTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 157
  • FIGURE 61 EUROPE ADALIMUMAB MARKET: SNAPSHOT (2019) 171
  • FIGURE 62 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019) 173
  • FIGURE 63 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 173
  • FIGURE 64 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 174
  • FIGURE 65 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 174
  • FIGURE 66 ASIA- PACIFIC ADALIMUMAB MARKET: SNAPSHOT (2019) 228
  • FIGURE 67 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019) 230
  • FIGURE 68 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 230
  • FIGURE 69 ASIA- PACIFIC ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 231
  • FIGURE 70 ASIA- PACIFIC ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 231
  • FIGURE 71 SOUTH AMERICA ADALIMUMAB MARKET: SNAPSHOT (2019) 270
  • FIGURE 72 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019) 272
  • FIGURE 73 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 272
  • FIGURE 74 SOUTH AMERICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 273
  • FIGURE 75 SOUTH AMERICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 273
  • FIGURE 76 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SNAPSHOT (2019) 288
  • FIGURE 77 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019) 290
  • FIGURE 78 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027) 290
  • FIGURE 79 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027) 291
  • FIGURE 80 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027) 291
  • FIGURE 81 GLOBAL ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 315
  • FIGURE 82 NORTH AMERICA ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 316
  • FIGURE 83 EUROPE ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 317
  • FIGURE 84 ASIA-PACIFIC ADALIMUMAB MARKET: COMPANY SHARE 2019 (%) 318
目次

Global adalimumab market is projected to register a CAGR of 4.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Adalimumab Market, By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Parenteral, Oral), Population Type (Adults, Children), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of global adalimumab market are:

Increasing geriatric population

Introduction to biosimilars

Market Players:

The key market players for global adalimumab market are listed below:

AbbVie Inc.

Amgen (Europe) GmbH (A Subsidiary of Amgen Inc.)

CELLTRION INC.

Samsung Bioepis (a subsidiary of Samsung Biologics)

Biogen

Coherus BioSciences

Innovent Biologics, Inc.

Mylan N.V.

Zydus Cadila

Hetero Biopharma Ltd.

Fresenius Kabi Deutschland GmbH (A Subsidiary of Fresenius Kabi AG)

Sandoz International GmbH (A Subsidiairy of Sandoz (A Division of Novartis AG))

Pfizer Inc.

Boehringer Ingelheim International GmbH

TABLE OF CONTENTS

1 INTRODUCTION 36

  • 1.1 OBJECTIVES OF THE STUDY 36
  • 1.2 MARKET DEFINITION 36
  • 1.3 OVERVIEW OF GLOBAL ADALIMUMAB MARKET 36
  • 1.4 LIMITATIONS 38
  • 1.5 MARKETS COVERED 40

2 MARKET SEGMENTATION 43

  • 2.1 MARKETS COVERED 43
  • 2.2 GEOGRAPHICAL SCOPE 44
  • 2.3 YEARS CONSIDERED FOR THE STUDY 45
  • 2.4 CURRENCY AND PRICING 45
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
  • 2.6 MULTIVARIATE MODELLING 49
  • 2.7 INDICATION LIFELINE CURVE 49
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
  • 2.9 DBMR MARKET POSITION GRID 51
  • 2.10 VENDOR SHARE ANALYSIS 52
  • 2.11 SECONDARY SOURCES 53
  • 2.12 ASSUMPTIONS 53

3 EXECUTIVE SUMMARY 54

  • 3.1 PIPELINE ANALYSIS 60

4 REGULATORY FRAMEWORK OF GLOBAL ADALIMUMAB MARKET 61

5 EPIDEMIOLOGY 64

6 ADALIMUMAB PRESCRIPTION 65

7 GLOBAL ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO 66

  • 7.1 REIMBURSEMENT SCENARIO IN THE U.S. 66
  • 7.2 REIMBURSEMENT SCENARIO IN CHINA 66
  • 7.3 REIMBURSEMENT SCENARIO IN JAPAN 66
  • 7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE 66
  • 7.5 REIMBURSEMENT SCENARIO IN DENMARK 66
  • 7.6 REIMBURSEMENT SCENARIO IN IRELAND 67

8 IMPACT OF BIOSIMILAR 68

9 MARKET OVERVIEW 69

  • 9.1 DRIVERS 71
    • 9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS 71
    • 9.1.2 INCREASING GERIATRIC POPULATION 72
    • 9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS 72
    • 9.1.4 INTRODUCTION TO BIOSIMILARS 74
    • 9.1.5 EXPLORATION OF EMERGING MARKETS 74
  • 9.2 RESTRAINTS 75
    • 9.2.1 HIGH COSTS OF DRUGS 75
    • 9.2.2 SIDE EFFECTS OF DRUGS 75
    • 9.2.3 CANCER CAUSING DRUGS 76
  • 9.3 OPPORTUNITIES 78
    • 9.3.1 PRESENCE OF PRODUCT PIPELINE 78
    • 9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 78
    • 9.3.3 INCREASING HEALTHCARE EXPENDITURE 79
    • 9.3.4 PRESENCE OF REIMBURSEMENT POLICIES 80
  • 9.4 CHALLENGES 80
    • 9.4.1 LOSS OF PATENTS 80
    • 9.4.2 AVAILABILITY OF ALTERNATIVES 81
    • 9.4.3 LONG APPROVAL PROCEDURE 82

10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY 83

  • 10.1 OVERVIEW 83
  • 10.2 ADALIMUMAB AND COVID-19 83
  • 10.3 PRICE IMPACT OF COVID-19 83
  • 10.4 IMPACT ON DEMAND 84
  • 10.5 IMPACT ON SUPPLY CHAIN 84
  • 10.6 STRATEGIC DECISIONS FOR MANUFACTURERS 85
  • 10.7 CONCLUSION 85

11 GLOBAL ADALIMUMAB MARKET, BY INDICATION 86

  • 11.1 OVERVIEW 87
  • 11.2 RHEUMATOID ARTHRITIS 90
  • 11.3 ANKYLOSING SPONDYLITIS 90
  • 11.4 CHRONIC PLAQUE PSORIASIS 91
  • 11.5 CROHN'S DISEASE 93
  • 11.6 ULCERATIVE COLITIS 94
  • 11.7 PSORIATIC ARTHRITIS 94
  • 11.8 JUVENILE IDIOPATHIC ARTHRITIS 95
  • 11.9 HIDRADENITIS SUPPURATIVA 96
  • 11.10 NON-INFECTIOUS INTERMEDIATE 97
  • 11.11 OTHERS 97

12 GLOBAL ADALIMUMAB MARKET, BY TYPE 99

  • 12.1 OVERVIEW 100
  • 12.2 BIOLOGICS 103
  • 12.3 BIOSIMILARS 103
    • 12.3.1 ADALIMUMAB-ATTO 104
    • 12.3.2 ADALIMUMAB-BWWD 104
    • 12.3.3 ADALIMUMAB-ADBM 104
    • 12.3.4 ADALIMUMAB-ADAZ 104
    • 12.3.5 ADALIMUMAB-FKJP 105
    • 12.3.6 ADALIMUMAB-AFZB 105
    • 12.3.7 OTHERS 105

13 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGTH 106

  • 13.1 OVERVIEW 107
  • 13.2 40MG/0.4ML 110
  • 13.3 80MG/0.8ML 110
  • 13.4 20MG/0.4ML 111
  • 13.5 10MG/0.1ML 112
  • 13.6 OTHERS 113

14 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE 114

  • 14.1 OVERVIEW 115
  • 14.2 BRANDED 118
  • 14.3 GENERICS 118
    • 14.3.1 AMJEVITA 119
    • 14.3.2 HYRIMOZ 119
    • 14.3.3 HULIO 119
    • 14.3.4 OTHERS 119

15 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 120

  • 15.1 OVERVIEW 121
  • 15.2 PARENTERAL 124
  • 15.3 ORAL 124

16 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE 126

  • 16.1 OVERVIEW 127
  • 16.2 ADULTS 130
  • 16.3 CHILDREN 130

17 GLOBAL ADALIMUMAB MARKET, BY END USER 132

  • 17.1 OVERVIEW 133
  • 17.2 HOSPITALS 136
  • 17.3 SPECIALTY CLINICS 136
  • 17.4 HOME HEALTHCARE 137
  • 17.5 OTHERS 138

18 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL 139

  • 18.1 OVERVIEW 140
  • 18.2 HOSPITAL PHARMACIES 143
  • 18.3 RETAIL PHARMACIES 143
  • 18.4 ONLINE PHARMACIES 144
  • 18.5 DIRECT TENDER 145
  • 18.6 OTHERS 145

19 GLOBAL ADALIMUMAB MARKET, BY GEOGRAPHY 147

  • 19.1 OVERVIEW 148
  • 19.2 NORTH AMERICA 154
    • 19.2.1 U.S. 162
    • 19.2.2 CANADA 165
    • 19.2.3 MEXICO 168
  • 19.3 EUROPE 171
    • 19.3.1 GERMANY 179
    • 19.3.2 U.K 182
    • 19.3.3 ITALY 185
    • 19.3.4 FRANCE 188
    • 19.3.5 SPAIN 191
    • 19.3.6 NETHERLANDS 194
    • 19.3.7 RUSSIA 197
    • 19.3.8 SWITZERLAND 200
    • 19.3.9 BELGIUM 203
    • 19.3.10 TURKEY 206
    • 19.3.11 AUSTRIA 209
    • 19.3.12 NORWAY 212
    • 19.3.13 HUNGARY 215
    • 19.3.14 LITHUANIA 218
    • 19.3.15 IRELAND 221
    • 19.3.16 POLAND 224
    • 19.3.17 REST OF EUROPE 227
  • 19.4 ASIA- PACIFIC 228
    • 19.4.1 JAPAN 236
    • 19.4.2 CHINA 239
    • 19.4.3 SOUTH KOREA 242
    • 19.4.4 AUSTRALIA 245
    • 19.4.5 INDIA 248
    • 19.4.6 SINGAPORE 251
    • 19.4.7 MALAYSIA 254
    • 19.4.8 THAILAND 257
    • 19.4.9 INDONESIA 260
    • 19.4.10 PHILIPPINES 263
    • 19.4.11 VIETNAM 266
    • 19.4.12 REST OF ASIA-PACIFIC 269
  • 19.5 SOUTH AMERICA 270
    • 19.5.1 BRAZIL 278
    • 19.5.2 ARGENTINA 281
    • 19.5.3 PERU 284
    • 19.5.4 REST OF SOUTH AMERICA 287
  • 19.6 MIDDLE EAST & AFRICA 288
    • 19.6.1 SAUDI ARABIA 296
    • 19.6.2 SOUTH AFRICA 299
    • 19.6.3 UAE 302
    • 19.6.4 ISRAEL 305
    • 19.6.5 KUWAIT 308
    • 19.6.6 EGYPT 311
    • 19.6.7 REST OF MIDDLE EAST & AFRICA 314

20 GLOBAL ADALIMUMAB MARKET: COMPANY LANDSCAPE 315

  • 20.1 COMPANY SHARE ANALYSIS: GLOBAL 315
  • 20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 316
  • 20.3 COMPANY SHARE ANALYSIS: EUROPE 317
  • 20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 318

21 SWOT 319

22 COMPANY PROFILES 320

  • 22.1 ABBVIE INC. 320
    • 22.1.1 COMPANY SNAPSHOT 320
    • 22.1.2 REVENUE ANALYSIS 320
    • 22.1.3 COMPANY SHARE ANALYSIS 321
    • 22.1.4 PRODUCT PORTFOLIO 321
    • 22.1.5 RECENT DEVELOPMENTS 321
  • 22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.) 323
    • 22.2.1 COMPANY SNAPSHOT 323
    • 22.2.2 REVENUE ANALYSIS 323
    • 22.2.3 COMPANY SHARE ANALYSIS 324
    • 22.2.4 PRODUCT PORTFOLIO 324
    • 22.2.5 RECENT DEVELOPMENTS 324
  • 22.3 BIOGEN 326
    • 22.3.1 COMPANY SNAPSHOT 326
    • 22.3.2 REVENUE ANALYSIS 326
    • 22.3.3 PRODUCT PORTFOLIO 327
    • 22.3.4 RECENT DEVELOPMENTS 327
  • 22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)} 328
    • 22.4.1 COMPANY SNAPSHOT 328
    • 22.4.2 REVENUE ANALYSIS 328
    • 22.4.3 PRODUCT PORTFOLIO 329
    • 22.4.4 RECENT DEVELOPMENTS 329
  • 22.5 MYLAN N.V. 330
    • 22.5.1 COMPANY SNAPSHOT 330
    • 22.5.2 REVENUE ANALYSIS 330
    • 22.5.3 PRODUCT PORTFOLIO 331
    • 22.5.4 RECENT DEVELOPMENTS 331
  • 22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 332
    • 22.6.1 COMPANY SNAPSHOT 332
    • 22.6.2 REVENUE ANALYSIS 332
    • 22.6.3 PRODUCT PORTFOLIO 332
    • 22.6.4 RECENT DEVELOPMENTS 333
  • 22.7 CELLTRION INC. 335
    • 22.7.1 COMPANY SNAPSHOT 335
    • 22.7.2 REVENUE ANALYSIS 335
    • 22.7.3 PRODUCT PORTFOLIO 336
    • 22.7.4 RECENT DEVELOPMENTS 336
  • 22.8 COHERUS BIOSCIENCES 337
    • 22.8.1 COMPANY SNAPSHOT 337
    • 22.8.2 PRODUCT PORTFOLIO 337
    • 22.8.3 RECENT DEVELOPMENTS 337
  • 22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG) 338
    • 22.9.1 COMPANY SNAPSHOT 338
    • 22.9.2 REVENUE ANALYSIS 338
    • 22.9.3 PRODUCT PORTFOLIO 338
    • 22.9.4 RECENT DEVELOPMENTS 339
  • 22.10 HETERO BIOPHARMA LTD. 341
    • 22.10.1 COMPANY SNAPSHOT 341
    • 22.10.2 PRODUCT PORTFOLIO 341
    • 22.10.3 RECENT DEVELOPMENTS 341
  • 22.11 INNOVENT BIOLOGICS, INC. 343
    • 22.11.1 COMPANY SNAPSHOT 343
    • 22.11.2 REVENUE ANALYSIS 343
    • 22.11.3 PRODUCT PORTFOLIO 344
    • 22.11.4 RECENT DEVELOPMENTS 344
  • 22.12 PFIZER INC. 345
    • 22.12.1 COMPANY SNAPSHOT 345
    • 22.12.2 REVENUE ANALYSIS 345
    • 22.12.3 PRODUCT PORTFOLIO 346
    • 22.12.4 RECENT DEVELOPMENTS 346
  • 22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED) 347
    • 22.13.1 COMPANY SNAPSHOT 347
    • 22.13.2 REVENUE ANALYSIS 347
    • 22.13.3 PRODUCT PORTFOLIO 348
    • 22.13.4 RECENT DEVELOPMENTS 348
  • 22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS) 349
    • 22.14.1 COMPANY SNAPSHOT 349
    • 22.14.2 REVENUE ANALYSIS 349
    • 22.14.3 PRODUCT PORTFOLIO 350
    • 22.14.4 RECENT DEVELOPMENTS 350
  • 22.15 ZYDUS CADILA 351
    • 22.15.1 COMPANY SNAPSHOT 351
    • 22.15.2 REVENUE ANALYSIS 351
    • 22.15.3 PRODUCT PORTFOLIO 352
    • 22.15.4 RECENT DEVELOPMENT 352

23 QUESTIONNAIRE 353

24 RELATED REPORTS 357